中国医药科学Issue(17)：100-101,125,3.
替吉奥与奈达铂加同步放疗治疗中晚期食管癌临床观察
S-1 plus nedaplatin and combined with concurrent radiotherapy in the treatment of medium and terminal esophageal cancer
董俊青1
作者信息
- 1. 山西省临汾市肿瘤医院放疗科，山西临汾041000
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of S-1 plus nedaplatin and combined with concurrent radiotherapy in the treatment of terminal esophageal cancer. Methods From June 2009 to December 2011, 62 patients with advanced squamous cell carcinoma of the esophagus were divided into two groups of the experimental group (30 cases) and the control group (32 cases). Radiotherapy was used cobalt 60-γ-line conventional fractionated irradiation. Results The overall response rate (CR+PR) of the experimental group and the control group were 86.7% and 62.5%respectively (P<0.05).The year survival rates of S1N chemoradiotherapy group and FP chemoradiotherapy group were 73.3%and 59.4%, the difference was not statistically significant (P>0.05). The main toxicities were nausea, vomting, marrow depression and radioactive esophagitis. The control group patients had more toxicities. All of them complete treating plan. Conclusion The short term curative effect of S-1 and nedaplatin in combination with radiotherapy is feasible for medium term and terminal esophageal cancer, and toxicity is tolerable.关键词
食管癌/化疗/放疗/替吉奥/奈达铂/顺氯氨铂/5-氟尿嘧啶Key words
Esophageal cancer/Chemotherapy/Radiotherapy/S-1/Nedaplatin/Cisplatin/Fluorouracil分类
医药卫生引用本文复制引用
董俊青..替吉奥与奈达铂加同步放疗治疗中晚期食管癌临床观察[J].中国医药科学,2013,(17):100-101,125,3.
